The TCOF1 antibody targets the Treacle protein, encoded by the *TCOF1* gene, which plays a critical role in ribosomal DNA (rDNA) transcription and ribosome biogenesis. Treacle is essential for craniofacial development, particularly in neural crest cell (NCC) proliferation, survival, and differentiation. Mutations in *TCOF1* are linked to Treacher Collins syndrome (TCS), a rare genetic disorder characterized by craniofacial malformations. TCOF1 antibodies are widely used in research to study Treacle's localization (primarily nucleolar), expression patterns, and molecular interactions, aiding in understanding the pathogenesis of TCS and related ribosomopathies. These antibodies enable techniques like Western blotting, immunofluorescence, and immunohistochemistry to assess protein levels, subcellular distribution, and functional aberrations in disease models. Recent studies also explore Treacle's role beyond TCS, including its involvement in cellular stress responses, DNA damage repair, and potential links to cancer. Commercial TCOF1 antibodies are typically validated in knockout cell lines to ensure specificity. Their application extends to developmental biology, translational research, and diagnostic investigations, offering insights into therapeutic strategies for ribosomal dysfunction disorders.